Anuh Pharma Ltd

- There is no mention of any current or planned fundraising through debt or equity in the transcript. - The company has not indicated plans for new equity issuance or debt raising in the discussion. - Focus appears to be on operational growth, increasing market share, and capital expenditure mainly related to capacity expansion (Rs. 40 to 50 lakhs in FY23) rather than raising external funds. - The conversation and queries were more centered around shareholding patterns, buyback suggestions, and realistic growth expectations rather than new fundraising. - No statements about issuing new shares or raising debts were made during the call or in management's closing remarks.

- The company plans capital expenditure of approximately Rs. 40 to 50 lakhs in FY23 to bring versatility in production capabilities by adding machinery. - They have previously made CAPEX of Rs. 70 crores in 2019, which expanded manufacturing capacity to 1500 tons; currently utilizing about 60% of this capacity. - Company focuses on R&D and plans to introduce five new API products in FY23 (Allopurinol, Acebrophylline, Citicoline, Theophylline, and Caffeine) to build a foundation for future growth. - There is no specific mention of strategic investments, but the company aims to increase market presence geographically (Vietnam, Japan, South Korea) and expand sales in the European market via CEP and WHO PQ filings.

- The company targets sales of Rs. 600 crores for FY 2023, showing optimism about demand resumption despite currently falling short. - Plans to introduce five new API products in FY23: Allopurinol, Acebrophylline, Citicoline, Theophylline, and Caffeine, to build growth foundation. - Focus on increasing market share of existing products and geographic expansion in Vietnam, Japan, and South Korea. - Approval filings (CEP for Gliclazide, Azithromycin and WHO PQ for Isoniazide) expected to open European market and institutional business, potentially adding Rs. 50 crore in sales within two years post-approval. - Manufacturing capacity utilization is about 60%, with potential to add 300 tons capacity by machinery addition. - R&D and compliance (environment, safety, GMP) are key pillars supporting sustainable growth. - Expect demand improvement post-pandemic and seasonally from June to October (monsoon period).

- Company targets Rs. 600 crores in sales for FY23, aiming for growth despite current shortfall. - Plans to introduce five new products (Allopurinol, Acebrophylline, Citicoline, Theophylline, Caffeine) in FY23 to build foundation for future growth. - Expects additional sales of at least Rs. 50 crores from European market approvals (CEP for Gliclazide, Azithromycin; WHO PQ for Isoniazide) within two years. - Focuses on increasing market share of existing products and expanding geographically (Vietnam, Japan, South Korea). - Company emphasizes R&D and operational efficiencies (cost reduction via solvent recovery, throughput increase, utility cost optimization). - Optimistic about demand recovery post-pandemic and seasonal uptick (antibiotics demand rising June-October). - Operating margin for FY22 was strong at 22.4%, with EBITDA Rs. 52 crores, indicating solid profitability foundation.

- The transcript does not explicitly mention the current or expected order book or pending orders for Anuh Pharma Limited. - However, the company reported a manufacturing volume of 867 tons in FY22 with a total capacity of 1500 tons, utilizing about 60% capacity. - For FY23, the company targets sales of Rs. 600 crores, expecting demand to improve with the reopening of most countries post-pandemic and seasonal demand increase from June to October. - They plan to launch five new products in FY23 (Allopurinol, Acebrophylline, Citicoline, Theophylline, and Caffeine) to build a foundation for growth. - Approval filings like CEP for Gliclazide, Azithromycin, and WHO PQ for Isoniazide are expected to unlock sales opportunities worth Rs. 50 crore over two years. - The company is optimistic regarding future demand and growth despite global inflation challenges.